US · Healthcare · Biotechnology
EPS came in at -0.68 against a street estimate of -0.72 — a beat of 5.6%.
Analysts rate Denali Therapeutics Inc a strong buy (19 buy, 0 hold, 0 sell out of 19) with an average price target of $36.06.
CONFIDENT AVLAYAH launched stronger than expected with $3.6M Q2 revenue and >50% payer coverage. Guidance raised to $10–12M Q3. Two Alzheimer's programs entered clinic. Pro forma cash $1.1B post-PRV sale. Q2 2026 No regional breakdown provided in call. Analysts pressed on bolus vs. sustainable growth, CNS distribution comparisons to intrathecal competitors, and biomarker expectations for tau program. Management acknowledged early demand exceeded forecast but emphasized expanding adoption to broader population and differentiation via even IV-delivered biodistribution vs. patchy intrathecal delivery. 2026-08-06…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 8.15% |
| Baillie Gifford & Co Limited. | 7.48% |
| T. Rowe Price Investment Management,Inc. | 5.33% |
| Temasek Holdings Ltd. | 4.39% |
| State Street Corp | 3.92% |
| Vanguard Capital Management, LLC | 3.85% |
| Vanguard Portfolio Management, LLC | 3.83% |
| FMR Inc | 2.86% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 DENALI THERAPEUTICS INC. — FORM 10-Q SUMMARY Quarter Ended June 30, 2026 --- HEADLINE NUMBERS • Cash and marketable securities combined: $940.0 mil | 2026-08-06 |
| Results announced · Q3 2026 DENALI THERAPEUTICS Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Q2 2026 net product revenue: $3.6 million (first full quarter of AVLAYAH co | 2026-08-06 |
| Acquisition completed · Q3 2026 DENALI THERAPEUTICS INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Company completed sale of Rare Pediatric Disease Priority Review Voucher (PRV) on Jul | 2026-07-28 |
| Material agreement · Q2 2026 DENALI THERAPEUTICS INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Company agreed to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $ | 2026-06-18 |
| Shareholder vote results · Q2 2026 DENALI THERAPEUTICS INC. - 8-K SUMMARY HEADLINE NUMBERS • 158,675,498 shares of common stock outstanding as of April 9, 2026 (record date) • 137,986 | 2026-06-04 |
| Quarterly report · Q1 2026 DENALI THERAPEUTICS INC. — Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash position: $387.6 million in cash and cash equivalents as of March 31, 2026 ( | 2026-05-07 |
| Proxy statement · Q4 2025 DENALI THERAPEUTICS INC. — 2026 PROXY STATEMENT SUMMARY CEO COMPENSATION • Ryan J. Watts (President and Chief Executive Officer) total compensation: | 2026-04-21 |
| Annual report FY2025 DENALI THERAPEUTICS INC. – FORM 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Market cap as of June 30, 2025: approximately $1.1 billion (bas | 2026-02-26 |
Readable in the app.
| Announcement | Date |
|---|---|
| 2026 Outlook Press Release Filed Denali Therapeutics filed an 8-K on January 6, 2026 to disclose a 2026 Outlook press release. The filing itself contains minimal substantive information—it consists primarily of standard SEC | 2026-01-06 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Denali Therapeutics Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.